Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 thr...

Full description

Saved in:
Bibliographic Details
Published inNature microbiology Vol. 5; no. 10; pp. 1185 - 1191
Main Authors Lee, Wen Shi, Wheatley, Adam K., Kent, Stephen J., DeKosky, Brandon J.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.10.2020
Nature Publishing Group
Subjects
13/1
631/250/255
631/61/24
Animals
Antibodies
Antibodies, Monoclonal - administration & dosage
Antibodies, Neutralizing - administration & dosage
Antibodies, Viral - administration & dosage
Antibodies, Viral - immunology
Antibody-Dependent Enhancement - immunology
Betacoronavirus - immunology
Biomedical and Life Sciences
Clinical trials
Coronavirus Infections - drug therapy
Coronavirus Infections - immunology
Coronavirus Infections - prevention & control
Coronavirus Infections - therapy
Coronaviruses
COVID-19
COVID-19 Drug Treatment
COVID-19 Serotherapy
COVID-19 Vaccines
Dengue fever
Humans
Immunization, Passive - adverse effects
In Vitro Techniques
Infectious Diseases
Life Sciences
Medical Microbiology
Microbiology
Models, Immunological
Pandemics - prevention & control
Parasitology
Perspective
Pneumonia, Viral - immunology
Pneumonia, Viral - prevention & control
Pneumonia, Viral - therapy
Respiratory syncytial virus
Respiratory Tract Diseases - etiology
Respiratory Tract Diseases - immunology
Risk Factors
Safety
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccines
Viral Vaccines - adverse effects
Viral Vaccines - immunology
Virology
Online AccessGet full text

Cover

Abstract Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2. Mechanisms of antibody-dependent enhancement of disease and mitigation strategies for SARS-CoV-2 vaccines and therapies are discussed.
AbstractList Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2.
Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2.Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2.
Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2.Mechanisms of antibody-dependent enhancement of disease and mitigation strategies for SARS-CoV-2 vaccines and therapies are discussed.
Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2. Mechanisms of antibody-dependent enhancement of disease and mitigation strategies for SARS-CoV-2 vaccines and therapies are discussed.
Author Kent, Stephen J.
DeKosky, Brandon J.
Lee, Wen Shi
Wheatley, Adam K.
Author_xml – sequence: 1
  givenname: Wen Shi
  orcidid: 0000-0001-7285-4054
  surname: Lee
  fullname: Lee, Wen Shi
  organization: Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity
– sequence: 2
  givenname: Adam K.
  orcidid: 0000-0002-5593-9387
  surname: Wheatley
  fullname: Wheatley, Adam K.
  organization: Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, ARC Centre for Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne
– sequence: 3
  givenname: Stephen J.
  orcidid: 0000-0002-8539-4891
  surname: Kent
  fullname: Kent, Stephen J.
  email: skent@unimelb.edu.au
  organization: Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, ARC Centre for Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University
– sequence: 4
  givenname: Brandon J.
  orcidid: 0000-0001-6406-0836
  surname: DeKosky
  fullname: DeKosky, Brandon J.
  email: dekosky@ku.edu
  organization: Department of Pharmaceutical Chemistry, The University of Kansas, Department of Chemical Engineering, The University of Kansas, Bioengineering Graduate Program, The University of Kansas
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32908214$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1rGzEQhkVwaJyPP5BDMfTSixpp9LHao3HbJBAI5KNXMSuN6w221pXWhfz7rmOnLTnkpEE8z8ww7zEbpS4RY-dSfJFCuYuipbGaCxBciMrV3BywMQjjuIHKjv6rj9hZKU9CCGnBWmc_sCMFtXAg9Zh9naa-bbr4zCOtKUVK_YTSAlOg1bbGFCf307t7Put-cJj8xhDaROXlv19QxnVL5ZQdznFZ6Gz_nrDH798eZlf85vbyeja94UHLuueKGkUEFoVWjTLO6eg02Ih1CKYCNUcboTEIShhZR4wwx1A1CFVF0KBUJ-zzru86d782VHq_akug5RITdZviQWtpt8cQA_rpDfrUbXIathuoStfOKVMP1Mc9tWlWFP06tyvMz_71PgMAOyDkrpRM87-IFH6bg9_l4Icc_EsO3gySeyOFtse-7VKfsV2-r6qdWoY56Sflf2u_Y_0Bys6Zxg
CitedBy_id crossref_primary_10_1007_s11596_021_2395_1
crossref_primary_10_1016_j_cossms_2021_100964
crossref_primary_10_4049_jimmunol_2200272
crossref_primary_10_1038_s41587_021_01131_y
crossref_primary_10_5662_wjm_v12_i4_200
crossref_primary_10_1016_j_csbj_2022_08_010
crossref_primary_10_1093_infdis_jiab421
crossref_primary_10_47183_mes_2023_040
crossref_primary_10_1002_eji_202149374
crossref_primary_10_1007_s42247_021_00175_9
crossref_primary_10_1016_j_vaccine_2023_03_005
crossref_primary_10_3389_fimmu_2022_974364
crossref_primary_10_1016_j_intimp_2022_108943
crossref_primary_10_1007_s41745_021_00268_8
crossref_primary_10_1007_s40820_021_00771_8
crossref_primary_10_1556_650_2021_32172
crossref_primary_10_3390_v14081739
crossref_primary_10_3346_jkms_2021_36_e54
crossref_primary_10_1126_science_abh1823
crossref_primary_10_1016_j_banm_2021_02_013
crossref_primary_10_3390_cells10030506
crossref_primary_10_1007_s11684_023_1021_y
crossref_primary_10_1016_j_cmi_2021_09_019
crossref_primary_10_2174_1568026622666220307125446
crossref_primary_10_1021_acs_molpharmaceut_1c00447
crossref_primary_10_1016_j_actbio_2022_09_048
crossref_primary_10_1161_HYPERTENSIONAHA_124_22064
crossref_primary_10_1093_femsre_fuab035
crossref_primary_10_3389_fcimb_2021_644574
crossref_primary_10_1016_j_cell_2021_06_021
crossref_primary_10_1038_s41541_022_00528_3
crossref_primary_10_1038_s41422_021_00531_8
crossref_primary_10_1186_s40779_021_00342_3
crossref_primary_10_1038_s41598_022_11374_7
crossref_primary_10_1038_s41590_022_01248_5
crossref_primary_10_1128_cmr_00200_21
crossref_primary_10_20411_pai_v7i1_491
crossref_primary_10_1084_jem_20202756
crossref_primary_10_1002_pro_4221
crossref_primary_10_1002_tre_802
crossref_primary_10_1093_abt_tbab006
crossref_primary_10_1007_s40123_021_00338_1
crossref_primary_10_1021_acs_jmedchem_3c01607
crossref_primary_10_1186_s40794_023_00212_x
crossref_primary_10_3390_pathogens10081030
crossref_primary_10_3390_v14081837
crossref_primary_10_3390_pathogens12040602
crossref_primary_10_1051_medsci_2021143
crossref_primary_10_1016_j_isci_2021_103006
crossref_primary_10_1016_j_virusres_2022_198711
crossref_primary_10_1016_j_heliyon_2023_e16847
crossref_primary_10_1146_annurev_med_042420_112725
crossref_primary_10_3390_v15071584
crossref_primary_10_1016_j_ijid_2021_07_015
crossref_primary_10_3390_v13040628
crossref_primary_10_1016_j_matt_2021_04_005
crossref_primary_10_1136_postgradmedj_2021_139835
crossref_primary_10_3389_fmicb_2020_588409
crossref_primary_10_3390_pathogens12020169
crossref_primary_10_1016_j_rmcr_2024_102096
crossref_primary_10_3389_fimmu_2023_1055457
crossref_primary_10_1016_j_cell_2021_05_005
crossref_primary_10_1016_j_ijbiomac_2023_128191
crossref_primary_10_3390_vaccines12050459
crossref_primary_10_1021_jacs_1c06600
crossref_primary_10_1021_acs_nanolett_3c04510
crossref_primary_10_1093_oxfimm_iqab018
crossref_primary_10_1038_s41467_023_40758_0
crossref_primary_10_4103_jfmpc_jfmpc_1975_21
crossref_primary_10_1056_NEJMoa2033130
crossref_primary_10_1016_j_celrep_2021_109164
crossref_primary_10_3390_covid3040038
crossref_primary_10_15252_embr_202357724
crossref_primary_10_1017_qrd_2021_12
crossref_primary_10_3390_j6020017
crossref_primary_10_1126_scitranslmed_abl8124
crossref_primary_10_1080_22221751_2021_1957400
crossref_primary_10_1089_vim_2021_0121
crossref_primary_10_1038_s41467_021_21037_2
crossref_primary_10_1097_MRM_0000000000000306
crossref_primary_10_1016_j_jddst_2021_102967
crossref_primary_10_1038_s41467_022_29909_x
crossref_primary_10_1016_j_coi_2022_102234
crossref_primary_10_1038_s41467_021_24979_9
crossref_primary_10_1111_jog_14748
crossref_primary_10_1016_j_heliyon_2024_e39941
crossref_primary_10_1038_s41392_022_01112_w
crossref_primary_10_2174_1872208315666211209094457
crossref_primary_10_1007_s40259_022_00529_7
crossref_primary_10_1021_acs_jmedchem_1c02000
crossref_primary_10_1016_j_medcli_2021_05_008
crossref_primary_10_1128_mBio_02395_21
crossref_primary_10_1038_s41541_021_00311_w
crossref_primary_10_1002_advs_202102181
crossref_primary_10_1371_journal_pone_0255169
crossref_primary_10_1016_j_meegid_2024_105626
crossref_primary_10_3390_life11080734
crossref_primary_10_15406_ijfcm_2022_06_00257
crossref_primary_10_7554_eLife_75228
crossref_primary_10_3389_fimmu_2021_637651
crossref_primary_10_1111_vox_13439
crossref_primary_10_1016_j_chom_2021_08_002
crossref_primary_10_1111_all_15441
crossref_primary_10_3389_fvets_2021_679248
crossref_primary_10_3390_v14030481
crossref_primary_10_1021_jacs_2c09870
crossref_primary_10_1038_s41577_024_01067_9
crossref_primary_10_1016_j_vaccine_2022_02_029
crossref_primary_10_2222_jsv_70_167
crossref_primary_10_7326_M20_8149
crossref_primary_10_1080_08830185_2022_2089666
crossref_primary_10_2217_rme_2022_0096
crossref_primary_10_1021_acsnano_1c01129
crossref_primary_10_3389_fimmu_2021_633184
crossref_primary_10_1016_j_xcrm_2022_100850
crossref_primary_10_1126_sciadv_abg7996
crossref_primary_10_1136_bmjopen_2020_045782
crossref_primary_10_3390_life11040298
crossref_primary_10_1128_Spectrum_01059_21
crossref_primary_10_1093_cid_ciab083
crossref_primary_10_1016_j_isci_2024_109703
crossref_primary_10_1016_j_biopha_2025_117936
crossref_primary_10_1016_j_ijid_2021_06_031
crossref_primary_10_1016_j_drudis_2021_04_018
crossref_primary_10_7554_eLife_86015
crossref_primary_10_3390_vaccines9101082
crossref_primary_10_4110_in_2021_21_e8
crossref_primary_10_1007_s42398_021_00175_9
crossref_primary_10_1186_s40779_021_00360_1
crossref_primary_10_1016_S2666_5247_23_00139_8
crossref_primary_10_2184_lsj_50_2_92
crossref_primary_10_1007_s11427_020_1859_y
crossref_primary_10_1556_650_2021_32210
crossref_primary_10_3324_haematol_2021_279289
crossref_primary_10_4049_jimmunol_2100272
crossref_primary_10_1080_08927022_2022_2111421
crossref_primary_10_1007_s10875_021_01193_2
crossref_primary_10_3390_pathogens12020233
crossref_primary_10_1186_s12951_021_00768_w
crossref_primary_10_1016_j_vaccine_2021_07_087
crossref_primary_10_1038_s41598_021_90797_0
crossref_primary_10_1080_22221751_2021_1957720
crossref_primary_10_3390_jcm10081580
crossref_primary_10_3390_diagnostics11060955
crossref_primary_10_1007_s12098_022_04266_1
crossref_primary_10_1080_21505594_2024_2441397
crossref_primary_10_1186_s12866_023_03080_9
crossref_primary_10_3389_fimmu_2021_657711
crossref_primary_10_1097_QAD_0000000000003050
crossref_primary_10_2174_1871526522666220425103031
crossref_primary_10_1038_s41392_021_00797_9
crossref_primary_10_1016_j_isci_2023_106256
crossref_primary_10_1016_j_isci_2023_107224
crossref_primary_10_1016_j_eclinm_2021_100843
crossref_primary_10_3389_fmicb_2024_1334152
crossref_primary_10_1007_s11357_021_00323_3
crossref_primary_10_3389_fimmu_2021_772511
crossref_primary_10_3390_microorganisms10030598
crossref_primary_10_1038_s41577_021_00542_x
crossref_primary_10_3389_fcimb_2021_598875
crossref_primary_10_1111_jpc_15232
crossref_primary_10_1002_med_21862
crossref_primary_10_3390_pharmaceutics14051101
crossref_primary_10_1016_j_medj_2022_08_002
crossref_primary_10_3390_vaccines12040417
crossref_primary_10_1038_s41392_022_00996_y
crossref_primary_10_1038_s41598_022_19780_7
crossref_primary_10_1038_s41598_022_19993_w
crossref_primary_10_1038_s41598_023_40277_4
crossref_primary_10_1093_infdis_jiab256
crossref_primary_10_1016_j_compbiomed_2022_106522
crossref_primary_10_1016_j_mattod_2023_04_008
crossref_primary_10_1371_journal_pone_0260714
crossref_primary_10_1002_adhm_202300351
crossref_primary_10_3389_fmicb_2022_845316
crossref_primary_10_1002_14651858_CD013825_pub2
crossref_primary_10_1016_j_apsb_2023_01_005
crossref_primary_10_3390_vaccines9020081
crossref_primary_10_1016_j_jiph_2021_02_012
crossref_primary_10_1093_jmcb_mjad062
crossref_primary_10_1142_S1793984421300107
crossref_primary_10_1016_j_ebiom_2022_104414
crossref_primary_10_3390_v13010134
crossref_primary_10_1007_s13205_022_03281_5
crossref_primary_10_1021_acsnano_0c07197
crossref_primary_10_1007_s00011_022_01582_2
crossref_primary_10_1038_s41467_021_21825_w
crossref_primary_10_1071_MA21010
crossref_primary_10_1007_s00204_021_03214_w
crossref_primary_10_1248_yakushi_21_00234_3
crossref_primary_10_1371_journal_pone_0253487
crossref_primary_10_47184_td_2021_01_04
crossref_primary_10_5817_CSF2022_1_3
crossref_primary_10_3390_jcm12144672
crossref_primary_10_1002_jmv_27292
crossref_primary_10_2139_ssrn_3986016
crossref_primary_10_1016_j_nantod_2022_101580
crossref_primary_10_4103_mjdrdypu_mjdrdypu_819_22
crossref_primary_10_1186_s13045_021_01046_w
crossref_primary_10_3389_fviro_2022_994843
crossref_primary_10_3390_vaccines9101168
crossref_primary_10_1002_eji_202049163
crossref_primary_10_1016_j_celrep_2022_111020
crossref_primary_10_1016_j_ebiom_2022_104424
crossref_primary_10_1556_650_2021_32414
crossref_primary_10_1038_s41573_022_00495_3
crossref_primary_10_1097_MRM_0000000000000393
crossref_primary_10_1002_14651858_CD014945
crossref_primary_10_1016_j_transci_2021_103063
crossref_primary_10_3389_fimmu_2022_1008285
crossref_primary_10_3389_fphys_2021_624675
crossref_primary_10_3390_vaccines10040608
crossref_primary_10_1038_s41586_021_04232_5
crossref_primary_10_1038_s41598_021_03273_0
crossref_primary_10_1038_s41390_023_02549_7
crossref_primary_10_1016_j_imj_2021_08_001
crossref_primary_10_1038_s41379_022_01069_9
crossref_primary_10_3390_v13081507
crossref_primary_10_14336_AD_2021_0611
crossref_primary_10_1631_jzus_B2200049
crossref_primary_10_1016_j_nantod_2021_101350
crossref_primary_10_1016_S1473_3099_21_00751_9
crossref_primary_10_1111_pai_13401
crossref_primary_10_3389_fimmu_2024_1505752
crossref_primary_10_3390_pharmaceutics12121247
crossref_primary_10_1016_j_isci_2022_104709
crossref_primary_10_1021_acs_biomac_2c00112
crossref_primary_10_3390_ijms23116078
crossref_primary_10_1080_08830185_2021_2019727
crossref_primary_10_1016_j_taap_2021_115796
crossref_primary_10_1016_j_isci_2022_104705
crossref_primary_10_1002_14651858_CD013825
crossref_primary_10_1007_s11033_022_07651_3
crossref_primary_10_1016_j_tim_2024_01_005
crossref_primary_10_1002_pd_5985
crossref_primary_10_1016_j_mehy_2021_110640
crossref_primary_10_1128_mBio_01987_21
crossref_primary_10_3390_vaccines9020178
crossref_primary_10_1007_s15010_023_02146_0
crossref_primary_10_1002_14651858_CD014945_pub2
crossref_primary_10_1007_s00284_021_02657_9
crossref_primary_10_3390_vaccines9080881
crossref_primary_10_1007_s11071_022_07939_w
crossref_primary_10_54044_RAMI_2021_01_07
crossref_primary_10_1007_s00508_020_01763_1
crossref_primary_10_3390_ijms231911364
crossref_primary_10_3390_vaccines9101195
crossref_primary_10_1172_JCI150613
crossref_primary_10_3389_ijph_2021_1603975
crossref_primary_10_3390_vaccines9070733
crossref_primary_10_1186_s12967_022_03382_y
crossref_primary_10_1089_jir_2024_0018
crossref_primary_10_1038_s41467_021_21239_8
crossref_primary_10_1021_acsnano_2c06803
crossref_primary_10_3390_v13112243
crossref_primary_10_1002_wnan_1785
crossref_primary_10_1099_jgv_0_001698
crossref_primary_10_3390_v13060957
crossref_primary_10_1080_21645515_2021_2006026
crossref_primary_10_3390_vaccines10070991
crossref_primary_10_47360_1995_4484_2020_469_479
crossref_primary_10_1016_j_jconrel_2021_10_023
crossref_primary_10_1186_s12879_021_06233_1
crossref_primary_10_1007_s11033_022_07493_z
crossref_primary_10_1111_trf_17485
crossref_primary_10_3390_ijerph17218155
crossref_primary_10_1126_scisignal_ade0326
crossref_primary_10_1002_cbin_11903
crossref_primary_10_1016_j_ejpb_2023_09_015
crossref_primary_10_1093_ckj_sfab073
crossref_primary_10_3390_ijms241310799
crossref_primary_10_1134_S0006297924010048
crossref_primary_10_3389_fvets_2022_1080927
crossref_primary_10_3390_vaccines11071240
crossref_primary_10_1126_sciadv_abn4188
crossref_primary_10_1002_jmv_27420
crossref_primary_10_1371_journal_pone_0257930
crossref_primary_10_5812_apid_136044
crossref_primary_10_1002_jmv_28997
crossref_primary_10_1021_acsinfecdis_1c00486
crossref_primary_10_1016_j_jointm_2021_04_003
crossref_primary_10_1038_s41579_020_00462_y
crossref_primary_10_1016_j_xcrm_2021_100191
crossref_primary_10_1093_jpids_piad113
crossref_primary_10_3390_vaccines13010065
crossref_primary_10_1016_j_antiviral_2023_105738
crossref_primary_10_1016_j_celrep_2021_109433
crossref_primary_10_1126_sciadv_abo1827
crossref_primary_10_1210_clinem_dgab055
crossref_primary_10_1016_j_vaccine_2021_12_024
crossref_primary_10_3389_fimmu_2022_782198
crossref_primary_10_3892_etm_2021_10843
crossref_primary_10_1002_ange_202100225
crossref_primary_10_1016_j_imlet_2023_05_007
crossref_primary_10_1080_14760584_2022_2071264
crossref_primary_10_1080_21645515_2021_1953351
crossref_primary_10_1016_j_applthermaleng_2021_117855
crossref_primary_10_1186_s12890_020_01361_x
crossref_primary_10_1007_s00103_022_03600_4
crossref_primary_10_3390_vaccines10122150
crossref_primary_10_2147_IJN_S427990
crossref_primary_10_1038_s41467_023_36561_6
crossref_primary_10_1016_j_lfs_2023_121907
crossref_primary_10_1021_acs_chemrev_2c00915
crossref_primary_10_3390_vaccines12030330
crossref_primary_10_5582_bst_2021_01227
crossref_primary_10_1007_s11356_021_14941_z
crossref_primary_10_1038_s41392_021_00653_w
crossref_primary_10_1136_bmjmed_2022_000427
crossref_primary_10_1016_S0140_6736_22_00101_5
crossref_primary_10_1002_path_5642
crossref_primary_10_1016_j_antiviral_2024_105834
crossref_primary_10_1371_journal_pone_0253758
crossref_primary_10_3389_fimmu_2022_941923
crossref_primary_10_3390_jcm11020405
crossref_primary_10_1002_jmv_27458
crossref_primary_10_1016_j_lana_2021_100079
crossref_primary_10_3389_fimmu_2020_581076
crossref_primary_10_3389_fimmu_2022_940715
crossref_primary_10_1007_s11684_021_0847_4
crossref_primary_10_3390_v14040827
crossref_primary_10_3389_fmed_2021_756922
crossref_primary_10_1016_j_isci_2023_106126
crossref_primary_10_3389_fimmu_2020_610688
crossref_primary_10_1002_jmv_29638
crossref_primary_10_15407_biotech16_06_069
crossref_primary_10_1186_s12879_022_07513_0
crossref_primary_10_1002_anie_202100225
crossref_primary_10_2222_jsv_71_1
crossref_primary_10_4103_jmms_jmms_93_21
crossref_primary_10_3390_microorganisms9122414
crossref_primary_10_7554_eLife_70330
crossref_primary_10_1172_JCI144685
crossref_primary_10_1155_2021_9673453
crossref_primary_10_1002_cti2_1269
crossref_primary_10_3389_fimmu_2022_859905
crossref_primary_10_1007_s12247_023_09713_w
crossref_primary_10_1016_j_celrep_2022_110904
crossref_primary_10_1016_j_addr_2020_12_011
crossref_primary_10_1093_infdis_jiac091
crossref_primary_10_1142_S2661341723720033
crossref_primary_10_1016_j_scr_2020_102125
crossref_primary_10_1080_08820139_2021_1936009
crossref_primary_10_1016_j_cytogfr_2021_03_001
crossref_primary_10_1016_j_jconrel_2023_06_025
crossref_primary_10_1371_journal_ppat_1012493
crossref_primary_10_2139_ssrn_3910133
crossref_primary_10_1016_j_isci_2021_103720
crossref_primary_10_1097_JBR_0000000000000144
crossref_primary_10_3390_ijms26051898
crossref_primary_10_1038_s41392_021_00750_w
crossref_primary_10_1016_j_jconrel_2021_03_043
crossref_primary_10_1186_s12879_022_07610_0
crossref_primary_10_3390_genes13122287
crossref_primary_10_3390_ijerph182011001
crossref_primary_10_1016_j_clicom_2021_10_001
crossref_primary_10_3389_fimmu_2021_757691
crossref_primary_10_1007_s15010_021_01664_z
crossref_primary_10_3390_vaccines10030349
crossref_primary_10_3390_vaccines9121376
crossref_primary_10_1002_prp2_691
crossref_primary_10_3390_v13081498
crossref_primary_10_3390_pathogens12070868
crossref_primary_10_1007_s00415_022_11188_7
crossref_primary_10_3390_antib14010004
crossref_primary_10_1126_sciadv_abl6015
crossref_primary_10_1016_j_vaccine_2025_126744
crossref_primary_10_1038_s41379_021_00814_w
crossref_primary_10_1371_journal_pbio_3001804
crossref_primary_10_35366_100075
crossref_primary_10_7759_cureus_24927
crossref_primary_10_1016_j_molimm_2022_11_010
crossref_primary_10_3389_fphar_2022_835136
crossref_primary_10_1016_j_ijid_2021_09_021
crossref_primary_10_1016_j_medcle_2021_05_003
crossref_primary_10_1016_j_addr_2020_12_006
crossref_primary_10_3390_v14061181
crossref_primary_10_1093_cid_ciab621
crossref_primary_10_1126_sciadv_abq6527
crossref_primary_10_2174_1568026623666230411095417
crossref_primary_10_2174_1874471014666211011122250
crossref_primary_10_3390_pathogens12121408
crossref_primary_10_1016_j_trsl_2021_02_006
crossref_primary_10_1093_intimm_dxab061
crossref_primary_10_1016_j_ijbiomac_2021_08_076
crossref_primary_10_1016_j_xcrp_2023_101249
crossref_primary_10_1089_hum_2021_052
crossref_primary_10_1038_s42003_021_01813_y
crossref_primary_10_1002_jssc_202300380
crossref_primary_10_1038_s41467_021_23173_1
crossref_primary_10_1126_scitranslmed_abg1143
crossref_primary_10_1016_j_lfs_2020_118919
crossref_primary_10_1371_journal_pone_0266923
crossref_primary_10_3390_biomedicines9040412
crossref_primary_10_1371_journal_ppat_1010155
crossref_primary_10_3389_fimmu_2021_730088
crossref_primary_10_23736_S2724_5276_22_06935_X
crossref_primary_10_3389_fcimb_2024_1384939
crossref_primary_10_3923_jpt_2022_50_57
crossref_primary_10_1177_20587384211050199
crossref_primary_10_3389_fimmu_2023_1183727
crossref_primary_10_3389_fcimb_2024_1346349
crossref_primary_10_3389_fviro_2021_815388
crossref_primary_10_1002_jcb_30017
crossref_primary_10_3390_vetsci9090470
crossref_primary_10_3390_biomed3010016
crossref_primary_10_1016_j_celrep_2022_110318
crossref_primary_10_1016_j_biomaterials_2020_120597
crossref_primary_10_31857_10_31857_S0320972524010042
crossref_primary_10_1002_advs_202100985
crossref_primary_10_1016_j_vaccine_2023_06_063
crossref_primary_10_3389_fimmu_2023_1204543
crossref_primary_10_1038_s41573_023_00672_y
crossref_primary_10_1111_jam_15340
crossref_primary_10_17816_MAJ108729
crossref_primary_10_1016_j_bbih_2023_100677
crossref_primary_10_1371_journal_ppat_1011596
crossref_primary_10_3389_fmolb_2021_654866
crossref_primary_10_3389_fimmu_2021_673699
crossref_primary_10_1126_scitranslmed_ado2817
crossref_primary_10_1097_IM9_0000000000000072
crossref_primary_10_1371_journal_pone_0271463
crossref_primary_10_1093_occmed_kqaa208
crossref_primary_10_3390_ijms241310583
crossref_primary_10_1007_s00011_022_01567_1
crossref_primary_10_1016_j_cell_2021_02_035
crossref_primary_10_1038_s41467_022_32867_z
crossref_primary_10_3390_v13122483
crossref_primary_10_1080_13543784_2022_2030310
crossref_primary_10_3390_v15122421
crossref_primary_10_1016_j_antiviral_2022_105271
crossref_primary_10_1093_jleuko_qiad143
crossref_primary_10_1021_acscentsci_1c00361
crossref_primary_10_3389_fimmu_2021_763098
crossref_primary_10_1002_prot_26140
crossref_primary_10_4103_cdr_cdr_48_21
crossref_primary_10_3390_v13061037
crossref_primary_10_3389_fimmu_2022_882972
crossref_primary_10_3390_molecules28124645
crossref_primary_10_1002_jmv_27613
crossref_primary_10_2174_1389201023666220507003726
crossref_primary_10_1038_s42003_022_03207_0
crossref_primary_10_7759_cureus_22669
crossref_primary_10_1016_j_jnma_2021_12_003
crossref_primary_10_1021_acsnano_3c07741
crossref_primary_10_1038_s41418_020_00711_w
crossref_primary_10_1073_pnas_2104847118
crossref_primary_10_1016_j_rmed_2021_106355
crossref_primary_10_1093_abt_tbac032
crossref_primary_10_1038_s41577_020_00480_0
crossref_primary_10_1016_j_cell_2021_02_026
crossref_primary_10_1371_journal_pone_0250780
crossref_primary_10_3389_fimmu_2022_882856
crossref_primary_10_3389_fmicb_2023_1117494
crossref_primary_10_1080_22221751_2021_1902245
crossref_primary_10_3390_pathogens12091108
crossref_primary_10_3390_antib13020028
crossref_primary_10_1186_s41231_021_00093_2
crossref_primary_10_1016_j_yrtph_2022_105189
crossref_primary_10_2147_ITT_S360151
crossref_primary_10_2174_2666796703666220623090158
crossref_primary_10_1371_journal_ppat_1011569
crossref_primary_10_1016_j_gene_2021_146134
crossref_primary_10_1016_j_immuni_2022_05_005
crossref_primary_10_1007_s00203_021_02265_y
crossref_primary_10_3389_fimmu_2023_1307398
crossref_primary_10_1016_j_addr_2021_113966
crossref_primary_10_3390_v14061127
crossref_primary_10_1186_s13578_021_00644_y
crossref_primary_10_1007_s12250_021_00371_1
crossref_primary_10_3389_fimmu_2021_660019
crossref_primary_10_1073_pnas_2026153118
crossref_primary_10_1038_s41392_022_00920_4
crossref_primary_10_3390_diagnostics13121990
crossref_primary_10_4103_abr_abr_134_23
Cites_doi 10.3851/IMP3243
10.1073/pnas.1402458111
10.1172/jci.insight.123158
10.1016/S0140-6736(20)30251-8
10.1016/S1473-3099(20)30232-2
10.1038/s41586-020-2381-y
10.1093/oxfordjournals.aje.a120955
10.1056/NEJMoa1800820
10.1038/s41586-020-2380-z
10.1126/science.abd0827
10.1172/JCI84428
10.1016/j.cell.2020.05.025
10.1084/jem.20020781
10.1001/jama.2020.10044
10.1126/science.abc5902
10.1002/jmv.1890360312
10.1038/nature02463
10.1016/j.vaccine.2006.08.011
10.4049/jimmunol.181.9.6337
10.1021/acsinfecdis.6b00006
10.1126/science.abb2507
10.1038/nm918
10.1056/NEJMp2005630
10.1371/journal.pone.0035421
10.1038/s41586-020-2169-0
10.1128/JVI.06048-11
10.1128/JVI.02980-14
10.1084/jem.146.1.201
10.1038/s41467-018-08165-y
10.1172/JCI122466
10.1016/j.cell.2020.02.052
10.1016/0147-9571(81)90003-5
10.1126/science.abc7520
10.1016/S0022-3476(68)80396-8
10.1016/S2213-2600(20)30193-4
10.1128/mBio.01753-18
10.1038/s41591-020-0965-6
10.1016/j.vaccine.2016.04.083
10.1016/S0140-6736(04)16501-X
10.1016/j.micinf.2020.02.006
10.1016/j.tim.2017.10.004
10.1128/JVI.00671-11
10.1128/JVI.78.22.12672-12676.2004
10.1371/journal.pmed.0030525
10.1080/21645515.2016.1177688
10.1128/JVI.75.5.2324-2330.2001
10.1093/infdis/jiz137
10.1128/JVI.02015-19
10.1126/science.aai8128
10.1126/science.abc1932
10.1073/pnas.0401939101
10.3201/eid1111.040659
10.1126/science.abb7269
10.1093/infdis/jit504
10.1073/pnas.1108360108
10.1016/S0140-6736(88)91657-1
10.1128/jvi.64.3.1407-1409.1990
10.1172/JCI138003
10.1038/s41421-020-0153-3
10.1007/BF01310476
10.1016/j.chest.2020.03.039
10.1136/bmj.m1443
10.1093/infdis/jiu396
10.1016/S0065-3527(03)60011-4
10.1007/s10096-004-1271-9
10.1128/JVI.79.12.7819-7826.2005
10.1001/jama.2020.4783
10.3389/fimmu.2017.00317
10.3389/fimmu.2019.00697
10.1126/science.abb2762
10.1186/1743-422X-11-82
10.1073/pnas.2004168117
10.3346/jkms.2020.35.e149
10.1016/j.vaccine.2005.06.038
10.1007/s12250-018-0009-2
10.1111/j.1537-2995.2012.03663.x
10.1073/pnas.1821317116
10.1292/jvms.60.49
10.1016/j.vaccine.2005.01.033
10.1073/pnas.86.12.4710
10.1126/science.1185181
10.1126/science.abc1731
10.1016/j.virol.2014.02.005
10.1038/nature06106
10.1203/PDR.0b013e3180686ce0
10.1128/JVI.77.13.7539-7544.2003
10.1371/journal.pone.0154461
10.1101/2020.03.29.20041962
10.1172/JCI140200
10.1093/cid/ciaa344
10.1016/j.cell.2020.08.017
10.1101/2020.06.07.137802
10.1101/2020.05.18.099507
10.1126/science.abc8511
10.1101/2020.03.24.006544
10.1093/cid/ciaa325
ContentType Journal Article
Copyright Springer Nature Limited 2020
Springer Nature Limited 2020.
Copyright_xml – notice: Springer Nature Limited 2020
– notice: Springer Nature Limited 2020.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
8FE
8FH
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M7P
PHGZM
PHGZT
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1038/s41564-020-00789-5
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest Biological Science Collection
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2058-5276
EndPage 1191
ExternalDocumentID 32908214
10_1038_s41564_020_00789_5
Genre Review
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: U.S. Department of Health & Human Services | National Institutes of Health (NIH)
  grantid: R21AI143407
  funderid: https://doi.org/10.13039/100000002
– fundername: Australian National Health and Medical Research Council (1162760) Australian National Health and Medical Research Council Fellowship
– fundername: COVID-19 Fast Grants The Jack Ma Foundation
– fundername: Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology Australian National Health and Medical Research Council (1149990) Australian National Health and Medical Research Council Fellowship
– fundername: NIH HHS
  grantid: DP5 OD023118
– fundername: NIAID NIH HHS
  grantid: R21 AI143407
GroupedDBID 0R~
53G
8FE
8FH
AAEEF
AAHBH
AARCD
AAYZH
AAZLF
ABJNI
ABLJU
ACBWK
ACGFS
ADBBV
AFBBN
AFKRA
AFSHS
AFWHJ
AHSBF
AIBTJ
ALFFA
ALMA_UNASSIGNED_HOLDINGS
ARMCB
AXYYD
BBNVY
BENPR
BHPHI
BKKNO
CCPQU
EBS
EJD
FSGXE
FZEXT
HCIFZ
HZ~
LK8
M7P
NNMJJ
O9-
ODYON
R9-
RNT
SHXYY
SIXXV
SNYQT
SOJ
TAOOD
TBHMF
TDRGL
TSG
AAYXX
ABFSG
ACSTC
AEZWR
AFANA
AFHIU
AHWEU
AIXLP
ATHPR
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NFIDA
NPM
PQGLB
AZQEC
DWQXO
GNUQQ
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
PUEGO
7X8
ID FETCH-LOGICAL-c419t-3eb3ee26a043b35884d8426da9cc5723fa6d2b5a230519dad2fac7ba277e2ba13
IEDL.DBID BENPR
ISSN 2058-5276
IngestDate Fri Jul 11 05:48:06 EDT 2025
Sat Aug 23 14:22:39 EDT 2025
Sun Jul 20 01:30:39 EDT 2025
Tue Jul 01 00:55:55 EDT 2025
Thu Apr 24 22:50:53 EDT 2025
Fri Feb 21 02:38:25 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c419t-3eb3ee26a043b35884d8426da9cc5723fa6d2b5a230519dad2fac7ba277e2ba13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0001-7285-4054
0000-0002-5593-9387
0000-0001-6406-0836
0000-0002-8539-4891
OpenAccessLink https://www.nature.com/articles/s41564-020-00789-5.pdf
PMID 32908214
PQID 2474988359
PQPubID 2069616
PageCount 7
ParticipantIDs proquest_miscellaneous_2441607890
proquest_journals_2474988359
pubmed_primary_32908214
crossref_primary_10_1038_s41564_020_00789_5
crossref_citationtrail_10_1038_s41564_020_00789_5
springer_journals_10_1038_s41564_020_00789_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-10-01
PublicationDateYYYYMMDD 2020-10-01
PublicationDate_xml – month: 10
  year: 2020
  text: 2020-10-01
  day: 01
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Nature microbiology
PublicationTitleAbbrev Nat Microbiol
PublicationTitleAlternate Nat Microbiol
PublicationYear 2020
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Nader, Horwitz, Rousseau (CR11) 1968; 72
Wang (CR30) 2017; 355
Zhou (CR45) 2014; 209
Bolles (CR57) 2011; 85
Bukreyev (CR72) 2004; 363
Sariol, Nogueira, Vasilakis (CR38) 2018; 26
Lu (CR2) 2020; 395
Zhang (CR95) 2020; 158
Weingartl (CR60) 2004; 78
Winarski (CR21) 2019; 116
Yip (CR42) 2016; 22
Honda-Okubo (CR62) 2015; 89
Polack (CR12) 2007; 62
Shi (CR80) 2020; 584
Ana-Sosa-Batiz (CR43) 2016; 11
CR47
Ye (CR20) 2017; 8
Hessell (CR86) 2007; 449
Ko (CR90) 2018; 23
Luo (CR68) 2018; 33
Halstead (CR83) 2003; 60
Wang (CR67) 2016; 2
London, Kimmelman (CR64) 2020; 368
Ahn (CR94) 2020; 35
Sridhar (CR14) 2018; 379
Qin (CR69) 2006; 24
Cheung (CR41) 2005; 79
Liu (CR85) 2019; 10
CR54
CR52
CR51
Agrawal (CR59) 2016; 12
Wan (CR39) 2020; 94
Hiatt (CR28) 2014; 111
Hashem (CR63) 2019; 220
Tseng (CR55) 2012; 7
Yan (CR5) 2020; 367
Long (CR50) 2020; 26
Dejnirattisai (CR13) 2010; 328
Jaume (CR40) 2011; 85
Crowley, Ackerman (CR88) 2019; 10
Ho (CR46) 2005; 11
Kam (CR70) 2007; 25
Liu (CR48) 2020; 20
Cao (CR81) 2020; 182
Yip (CR32) 2014; 11
Li (CR97) 2020; 324
Hui (CR31) 2020; 8
Hohdatsu, Nakamura, Ishizuka, Yamada, Koyama (CR18) 1991; 120
Vennema (CR17) 1990; 64
Shen (CR92) 2020; 323
Takada, Feldmann, Ksiazek, Kawaoka (CR36) 2003; 77
Hoffmann (CR4) 2020; 181
Gralinski (CR25) 2018; 9
CR75
Liu (CR66) 2019; 4
Hansen (CR78) 2020; 369
Wrapp (CR8) 2020; 367
Lam (CR3) 2020; 583
Cheng (CR91) 2005; 24
Ochiai (CR37) 1992; 36
Deming (CR56) 2006; 3
CR6
CR7
Tetro (CR53) 2020; 22
Weiss, Scott (CR19) 1981; 4
Yasui (CR58) 2008; 181
Czub, Weingartl, Czub, He, Cao (CR61) 2005; 23
Yuan (CR79) 2020; 368
Polack (CR22) 2002; 196
Brouwer (CR77) 2020; 369
Bisht (CR73) 2004; 101
Pandey, Vyas (CR100) 2012; 52
Zheng (CR49) 2020; 369
Robinson (CR34) 1989; 86
Graham (CR10) 2016; 34
Halstead, O’Rourke (CR16) 1977; 146
Mair-Jenkins (CR89) 2015; 211
Duan (CR93) 2020; 117
Rogers (CR82) 2020; 369
Hohdatsu (CR15) 1998; 60
Yang (CR71) 2004; 428
Parsons (CR87) 2019; 129
CR98
Kim (CR9) 1969; 89
CR96
DiLillo, Palese, Wilson, Ravetch (CR84) 2016; 126
Takada, Watanabe, Okazaki, Kida, Kawaoka (CR35) 2001; 75
Polack, Hoffman, Crujeiras, Griffin (CR23) 2003; 9
Zhou (CR1) 2020; 6
Robinson, Montefiori, Mitchell (CR33) 1988; 1
Lurie, Saville, Hatchett, Halton (CR65) 2020; 382
Zeitlin (CR29) 2011; 108
Ju (CR76) 2020; 584
Casadevall, Pirofski (CR99) 2020; 130
CR27
CR26
CR24
Gao (CR74) 2020; 369
Yasui (CR44) 2014; 454–455
H Vennema (789_CR17) 1990; 64
789_CR24
789_CR26
789_CR27
BS Graham (789_CR10) 2016; 34
S Sridhar (789_CR14) 2018; 379
TF Rogers (789_CR82) 2020; 369
TT Wang (789_CR30) 2017; 355
M Czub (789_CR61) 2005; 23
M Bolles (789_CR57) 2011; 85
AS Agrawal (789_CR59) 2016; 12
F Yasui (789_CR44) 2014; 454–455
J Mair-Jenkins (789_CR89) 2015; 211
TT Lam (789_CR3) 2020; 583
Y Zhou (789_CR1) 2020; 6
CA Sariol (789_CR38) 2018; 26
R Yan (789_CR5) 2020; 367
789_CR7
C Shen (789_CR92) 2020; 323
789_CR6
M Jaume (789_CR40) 2011; 85
Y Cheng (789_CR91) 2005; 24
ZW Ye (789_CR20) 2017; 8
MS Yip (789_CR32) 2014; 11
FP Polack (789_CR22) 2002; 196
D Deming (789_CR56) 2006; 3
YW Kam (789_CR70) 2007; 25
J Zhou (789_CR45) 2014; 209
AJ London (789_CR64) 2020; 368
N Lurie (789_CR65) 2020; 382
J Hansen (789_CR78) 2020; 369
MS Yip (789_CR42) 2016; 22
Y Liu (789_CR48) 2020; 20
PR Nader (789_CR11) 1968; 72
JH Ko (789_CR90) 2018; 23
MS Parsons (789_CR87) 2019; 129
D Wrapp (789_CR8) 2020; 367
F Luo (789_CR68) 2018; 33
FP Polack (789_CR12) 2007; 62
F Yasui (789_CR58) 2008; 181
H Weingartl (789_CR60) 2004; 78
SB Halstead (789_CR83) 2003; 60
KPY Hui (789_CR31) 2020; 8
S Pandey (789_CR100) 2012; 52
K Duan (789_CR93) 2020; 117
Y Liu (789_CR85) 2019; 10
789_CR98
Y Honda-Okubo (789_CR62) 2015; 89
AJ Hessell (789_CR86) 2007; 449
JY Ahn (789_CR94) 2020; 35
Y Cao (789_CR81) 2020; 182
DJ DiLillo (789_CR84) 2016; 126
M Hoffmann (789_CR4) 2020; 181
789_CR96
RC Weiss (789_CR19) 1981; 4
KL Winarski (789_CR21) 2019; 116
CY Cheung (789_CR41) 2005; 79
AR Crowley (789_CR88) 2019; 10
S Zheng (789_CR49) 2020; 369
Q Wang (789_CR67) 2016; 2
R Lu (789_CR2) 2020; 395
FP Polack (789_CR23) 2003; 9
E Qin (789_CR69) 2006; 24
LE Gralinski (789_CR25) 2018; 9
AM Hashem (789_CR63) 2019; 220
W Dejnirattisai (789_CR13) 2010; 328
PJM Brouwer (789_CR77) 2020; 369
QX Long (789_CR50) 2020; 26
T Hohdatsu (789_CR18) 1991; 120
MS Ho (789_CR46) 2005; 11
789_CR75
WE Robinson Jr (789_CR34) 1989; 86
M Yuan (789_CR79) 2020; 368
SB Halstead (789_CR16) 1977; 146
A Hiatt (789_CR28) 2014; 111
Q Gao (789_CR74) 2020; 369
A Takada (789_CR36) 2003; 77
HW Kim (789_CR9) 1969; 89
L Zeitlin (789_CR29) 2011; 108
789_CR47
H Bisht (789_CR73) 2004; 101
JA Tetro (789_CR53) 2020; 22
CT Tseng (789_CR55) 2012; 7
L Li (789_CR97) 2020; 324
H Ochiai (789_CR37) 1992; 36
L Liu (789_CR66) 2019; 4
A Casadevall (789_CR99) 2020; 130
WE Robinson Jr (789_CR33) 1988; 1
789_CR54
T Hohdatsu (789_CR15) 1998; 60
F Ana-Sosa-Batiz (789_CR43) 2016; 11
ZY Yang (789_CR71) 2004; 428
Y Wan (789_CR39) 2020; 94
789_CR51
789_CR52
B Zhang (789_CR95) 2020; 158
B Ju (789_CR76) 2020; 584
R Shi (789_CR80) 2020; 584
A Takada (789_CR35) 2001; 75
A Bukreyev (789_CR72) 2004; 363
References_xml – volume: 23
  start-page: 617
  year: 2018
  end-page: 622
  ident: CR90
  article-title: Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience
  publication-title: Antivir. Ther.
  doi: 10.3851/IMP3243
– volume: 111
  start-page: 5992
  year: 2014
  end-page: 5997
  ident: CR28
  article-title: Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1402458111
– volume: 4
  start-page: e123158
  year: 2019
  ident: CR66
  article-title: Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.123158
– ident: CR51
– volume: 395
  start-page: 565
  year: 2020
  end-page: 574
  ident: CR2
  article-title: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30251-8
– volume: 20
  start-page: 656
  year: 2020
  end-page: 657
  ident: CR48
  article-title: Viral dynamics in mild and severe cases of COVID-19
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(20)30232-2
– ident: CR54
– volume: 584
  start-page: 120
  year: 2020
  end-page: 124
  ident: CR80
  article-title: A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
  publication-title: Nature
  doi: 10.1038/s41586-020-2381-y
– volume: 89
  start-page: 422
  year: 1969
  end-page: 434
  ident: CR9
  article-title: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
  publication-title: Am. J. Epidemiol.
  doi: 10.1093/oxfordjournals.aje.a120955
– volume: 379
  start-page: 327
  year: 2018
  end-page: 340
  ident: CR14
  article-title: Effect of dengue serostatus on dengue vaccine safety and efficacy
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1800820
– volume: 584
  start-page: 115
  year: 2020
  end-page: 119
  ident: CR76
  article-title: Human neutralizing antibodies elicited by SARS-CoV-2 infection
  publication-title: Nature
  doi: 10.1038/s41586-020-2380-z
– volume: 369
  start-page: 1010
  year: 2020
  end-page: 1014
  ident: CR78
  article-title: Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
  publication-title: Science
  doi: 10.1126/science.abd0827
– volume: 126
  start-page: 605
  year: 2016
  end-page: 610
  ident: CR84
  article-title: Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI84428
– volume: 182
  start-page: 73
  year: 2020
  end-page: 84
  ident: CR81
  article-title: Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells
  publication-title: Cell
  doi: 10.1016/j.cell.2020.05.025
– volume: 196
  start-page: 859
  year: 2002
  end-page: 865
  ident: CR22
  article-title: A role for immune complexes in enhanced respiratory syncytial virus disease
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20020781
– volume: 324
  start-page: 460
  year: 2020
  end-page: 470
  ident: CR97
  article-title: Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial
  publication-title: JAMA
  doi: 10.1001/jama.2020.10044
– volume: 369
  start-page: 643
  year: 2020
  end-page: 650
  ident: CR77
  article-title: Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
  publication-title: Science
  doi: 10.1126/science.abc5902
– volume: 36
  start-page: 217
  year: 1992
  end-page: 221
  ident: CR37
  article-title: Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.1890360312
– volume: 428
  start-page: 561
  year: 2004
  end-page: 564
  ident: CR71
  article-title: A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
  publication-title: Nature
  doi: 10.1038/nature02463
– volume: 25
  start-page: 729
  year: 2007
  end-page: 740
  ident: CR70
  article-title: Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2006.08.011
– volume: 181
  start-page: 6337
  year: 2008
  end-page: 6348
  ident: CR58
  article-title: Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.181.9.6337
– ident: CR47
– volume: 2
  start-page: 361
  year: 2016
  end-page: 376
  ident: CR67
  article-title: Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates
  publication-title: ACS Infect. Dis.
  doi: 10.1021/acsinfecdis.6b00006
– volume: 367
  start-page: 1260
  year: 2020
  end-page: 1263
  ident: CR8
  article-title: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
  publication-title: Science
  doi: 10.1126/science.abb2507
– volume: 9
  start-page: 1209
  year: 2003
  end-page: 1213
  ident: CR23
  article-title: A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles
  publication-title: Nat. Med.
  doi: 10.1038/nm918
– volume: 382
  start-page: 1969
  year: 2020
  end-page: 1973
  ident: CR65
  article-title: Developing Covid-19 vaccines at pandemic speed
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMp2005630
– volume: 7
  start-page: e35421
  year: 2012
  ident: CR55
  article-title: Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0035421
– volume: 583
  start-page: 282
  year: 2020
  end-page: 285
  ident: CR3
  article-title: Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins
  publication-title: Nature
  doi: 10.1038/s41586-020-2169-0
– volume: 85
  start-page: 12201
  year: 2011
  end-page: 12215
  ident: CR57
  article-title: A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge
  publication-title: J. Virol.
  doi: 10.1128/JVI.06048-11
– ident: CR6
– volume: 89
  start-page: 2995
  year: 2015
  end-page: 3007
  ident: CR62
  article-title: Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology
  publication-title: J. Virol.
  doi: 10.1128/JVI.02980-14
– ident: CR27
– volume: 146
  start-page: 201
  year: 1977
  end-page: 217
  ident: CR16
  article-title: Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.146.1.201
– volume: 10
  year: 2019
  ident: CR85
  article-title: Cross-lineage protection by human antibodies binding the influenza B hemagglutinin
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-08165-y
– volume: 129
  start-page: 182
  year: 2019
  end-page: 191
  ident: CR87
  article-title: Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI122466
– volume: 181
  start-page: 271
  year: 2020
  end-page: 280
  ident: CR4
  article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.052
– volume: 4
  start-page: 175
  year: 1981
  end-page: 189
  ident: CR19
  article-title: Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever
  publication-title: Comp. Immunol. Microbiol. Infect. Dis.
  doi: 10.1016/0147-9571(81)90003-5
– volume: 22
  start-page: 25
  year: 2016
  end-page: 31
  ident: CR42
  article-title: Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS
  publication-title: Hong Kong Med. J.
– volume: 369
  start-page: 956
  year: 2020
  end-page: 963
  ident: CR82
  article-title: Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
  publication-title: Science
  doi: 10.1126/science.abc7520
– volume: 72
  start-page: 22
  year: 1968
  end-page: 28
  ident: CR11
  article-title: Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine
  publication-title: J. Pediatr.
  doi: 10.1016/S0022-3476(68)80396-8
– ident: CR52
– volume: 8
  start-page: 687
  year: 2020
  end-page: 695
  ident: CR31
  article-title: Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures
  publication-title: Lancet Respir. Med.
  doi: 10.1016/S2213-2600(20)30193-4
– volume: 9
  start-page: e01753-18
  year: 2018
  ident: CR25
  article-title: Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis
  publication-title: mBio
  doi: 10.1128/mBio.01753-18
– volume: 26
  start-page: 1200
  year: 2020
  end-page: 1204
  ident: CR50
  article-title: Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0965-6
– volume: 34
  start-page: 3535
  year: 2016
  end-page: 3541
  ident: CR10
  article-title: Vaccines against respiratory syncytial virus: the time has finally come
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2016.04.083
– volume: 363
  start-page: 2122
  year: 2004
  end-page: 2127
  ident: CR72
  article-title: Mucosal immunisation of African green monkeys ( ) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS
  publication-title: Lancet
  doi: 10.1016/S0140-6736(04)16501-X
– ident: CR24
– volume: 22
  start-page: 72
  year: 2020
  end-page: 73
  ident: CR53
  article-title: Is COVID-19 receiving ADE from other coronaviruses?
  publication-title: Microbes Infect.
  doi: 10.1016/j.micinf.2020.02.006
– volume: 26
  start-page: 186
  year: 2018
  end-page: 190
  ident: CR38
  article-title: A tale of two viruses: does heterologous flavivirus immunity enhance Zika disease?
  publication-title: Trends Microbiol.
  doi: 10.1016/j.tim.2017.10.004
– volume: 85
  start-page: 10582
  year: 2011
  end-page: 10597
  ident: CR40
  article-title: Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway
  publication-title: J. Virol.
  doi: 10.1128/JVI.00671-11
– volume: 78
  start-page: 12672
  year: 2004
  end-page: 12676
  ident: CR60
  article-title: Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets
  publication-title: J. Virol.
  doi: 10.1128/JVI.78.22.12672-12676.2004
– volume: 3
  start-page: e525
  year: 2006
  ident: CR56
  article-title: Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants
  publication-title: PLoS Med.
  doi: 10.1371/journal.pmed.0030525
– volume: 12
  start-page: 2351
  year: 2016
  end-page: 2356
  ident: CR59
  article-title: Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.1080/21645515.2016.1177688
– volume: 75
  start-page: 2324
  year: 2001
  end-page: 2330
  ident: CR35
  article-title: Infectivity-enhancing antibodies to Ebola virus glycoprotein
  publication-title: J. Virol.
  doi: 10.1128/JVI.75.5.2324-2330.2001
– volume: 220
  start-page: 1558
  year: 2019
  end-page: 1567
  ident: CR63
  article-title: A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiz137
– volume: 94
  start-page: e02015-19
  year: 2020
  ident: CR39
  article-title: Molecular mechanism for antibody-dependent enhancement of coronavirus entry
  publication-title: J. Virol.
  doi: 10.1128/JVI.02015-19
– volume: 355
  start-page: 395
  year: 2017
  end-page: 398
  ident: CR30
  article-title: IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity
  publication-title: Science
  doi: 10.1126/science.aai8128
– volume: 369
  start-page: 77
  year: 2020
  end-page: 81
  ident: CR74
  article-title: Rapid development of an inactivated vaccine candidate for SARS-CoV-2
  publication-title: Science
  doi: 10.1126/science.abc1932
– volume: 101
  start-page: 6641
  year: 2004
  end-page: 6646
  ident: CR73
  article-title: Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0401939101
– volume: 11
  start-page: 1730
  year: 2005
  end-page: 1737
  ident: CR46
  article-title: Neutralizing antibody response and SARS severity
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid1111.040659
– volume: 368
  start-page: 630
  year: 2020
  end-page: 633
  ident: CR79
  article-title: A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
  publication-title: Science
  doi: 10.1126/science.abb7269
– volume: 209
  start-page: 1331
  year: 2014
  end-page: 1342
  ident: CR45
  article-title: Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jit504
– ident: CR96
– volume: 108
  start-page: 20690
  year: 2011
  end-page: 20694
  ident: CR29
  article-title: Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1108360108
– ident: CR75
– volume: 1
  start-page: 790
  year: 1988
  end-page: 794
  ident: CR33
  article-title: Antibody-dependent enhancement of human immunodeficiency virus type 1 infection
  publication-title: Lancet
  doi: 10.1016/S0140-6736(88)91657-1
– volume: 64
  start-page: 1407
  year: 1990
  end-page: 1409
  ident: CR17
  article-title: Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization
  publication-title: J. Virol.
  doi: 10.1128/jvi.64.3.1407-1409.1990
– volume: 130
  start-page: 1545
  year: 2020
  end-page: 1548
  ident: CR99
  article-title: The convalescent sera option for containing COVID-19
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI138003
– volume: 6
  start-page: 14
  year: 2020
  ident: CR1
  article-title: Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
  publication-title: Cell Discov.
  doi: 10.1038/s41421-020-0153-3
– volume: 120
  start-page: 207
  year: 1991
  end-page: 217
  ident: CR18
  article-title: A study on the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection in feline macrophages by monoclonal antibodies
  publication-title: Arch. Virol.
  doi: 10.1007/BF01310476
– volume: 158
  start-page: e9
  year: 2020
  end-page: e13
  ident: CR95
  article-title: Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection
  publication-title: Chest
  doi: 10.1016/j.chest.2020.03.039
– volume: 369
  start-page: m1443
  year: 2020
  ident: CR49
  article-title: Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study
  publication-title: BMJ
  doi: 10.1136/bmj.m1443
– volume: 211
  start-page: 80
  year: 2015
  end-page: 90
  ident: CR89
  article-title: The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiu396
– volume: 60
  start-page: 421
  year: 2003
  end-page: 467
  ident: CR83
  article-title: Neutralization and antibody-dependent enhancement of dengue viruses
  publication-title: Adv. Virus. Res.
  doi: 10.1016/S0065-3527(03)60011-4
– volume: 24
  start-page: 44
  year: 2005
  end-page: 46
  ident: CR91
  article-title: Use of convalescent plasma therapy in SARS patients in Hong Kong.
  publication-title: J. Clin. Microbiol. Infect. Dis.
  doi: 10.1007/s10096-004-1271-9
– volume: 79
  start-page: 7819
  year: 2005
  end-page: 7826
  ident: CR41
  article-title: Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.12.7819-7826.2005
– ident: CR26
– volume: 323
  start-page: 1582
  year: 2020
  end-page: 1589
  ident: CR92
  article-title: Treatment of 5 critically ill patients with COVID-19 with convalescent plasma
  publication-title: JAMA
  doi: 10.1001/jama.2020.4783
– volume: 8
  start-page: 317
  year: 2017
  ident: CR20
  article-title: Antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin head region of pandemic H1N1 influenza virus play detrimental roles in H1N1-infected mice
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.00317
– volume: 10
  start-page: 69
  year: 2019
  ident: CR88
  article-title: Mind the gap: how interspecies variability in IgG and its receptors may complicate comparisons of human and non-human primate effector function
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.00697
– volume: 367
  start-page: 1444
  year: 2020
  end-page: 1448
  ident: CR5
  article-title: Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
  publication-title: Science
  doi: 10.1126/science.abb2762
– volume: 11
  start-page: 82
  year: 2014
  ident: CR32
  article-title: Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus
  publication-title: Virol. J.
  doi: 10.1186/1743-422X-11-82
– volume: 117
  start-page: 9490
  year: 2020
  end-page: 9496
  ident: CR93
  article-title: Effectiveness of convalescent plasma therapy in severe COVID-19 patients
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2004168117
– volume: 35
  start-page: e149
  year: 2020
  ident: CR94
  article-title: Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea
  publication-title: J. Korean Med. Sci.
  doi: 10.3346/jkms.2020.35.e149
– volume: 24
  start-page: 1028
  year: 2006
  end-page: 1034
  ident: CR69
  article-title: Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2005.06.038
– volume: 33
  start-page: 201
  year: 2018
  end-page: 204
  ident: CR68
  article-title: Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine
  publication-title: Virol. Sin.
  doi: 10.1007/s12250-018-0009-2
– volume: 52
  start-page: 65S
  issue: Suppl. 1
  year: 2012
  end-page: 79S
  ident: CR100
  article-title: Adverse effects of plasma transfusion
  publication-title: Transfusion
  doi: 10.1111/j.1537-2995.2012.03663.x
– ident: CR98
– volume: 116
  start-page: 15194
  year: 2019
  end-page: 15199
  ident: CR21
  article-title: Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1821317116
– volume: 60
  start-page: 49
  year: 1998
  end-page: 55
  ident: CR15
  article-title: Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus
  publication-title: J. Vet. Med. Sci.
  doi: 10.1292/jvms.60.49
– volume: 23
  start-page: 2273
  year: 2005
  end-page: 2279
  ident: CR61
  article-title: Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2005.01.033
– volume: 86
  start-page: 4710
  year: 1989
  end-page: 4714
  ident: CR34
  article-title: Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.86.12.4710
– volume: 328
  start-page: 745
  year: 2010
  end-page: 748
  ident: CR13
  article-title: Cross-reacting antibodies enhance dengue virus infection in humans
  publication-title: Science
  doi: 10.1126/science.1185181
– ident: CR7
– volume: 368
  start-page: 476
  year: 2020
  end-page: 477
  ident: CR64
  article-title: Against pandemic research exceptionalism
  publication-title: Science
  doi: 10.1126/science.abc1731
– volume: 454–455
  start-page: 157
  year: 2014
  end-page: 168
  ident: CR44
  article-title: Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus
  publication-title: Virology
  doi: 10.1016/j.virol.2014.02.005
– volume: 449
  start-page: 101
  year: 2007
  end-page: 104
  ident: CR86
  article-title: Fc receptor but not complement binding is important in antibody protection against HIV
  publication-title: Nature
  doi: 10.1038/nature06106
– volume: 62
  start-page: 111
  year: 2007
  end-page: 115
  ident: CR12
  article-title: Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple
  publication-title: Pediatr. Res.
  doi: 10.1203/PDR.0b013e3180686ce0
– volume: 77
  start-page: 7539
  year: 2003
  end-page: 7544
  ident: CR36
  article-title: Antibody-dependent enhancement of Ebola virus infection
  publication-title: J. Virol.
  doi: 10.1128/JVI.77.13.7539-7544.2003
– volume: 11
  start-page: e0154461
  year: 2016
  ident: CR43
  article-title: Influenza-specific antibody-dependent phagocytosis
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0154461
– volume: 369
  start-page: 956
  year: 2020
  ident: 789_CR82
  publication-title: Science
  doi: 10.1126/science.abc7520
– volume: 22
  start-page: 25
  year: 2016
  ident: 789_CR42
  publication-title: Hong Kong Med. J.
– volume: 324
  start-page: 460
  year: 2020
  ident: 789_CR97
  publication-title: JAMA
  doi: 10.1001/jama.2020.10044
– ident: 789_CR24
  doi: 10.1101/2020.03.29.20041962
– volume: 182
  start-page: 73
  year: 2020
  ident: 789_CR81
  publication-title: Cell
  doi: 10.1016/j.cell.2020.05.025
– volume: 584
  start-page: 115
  year: 2020
  ident: 789_CR76
  publication-title: Nature
  doi: 10.1038/s41586-020-2380-z
– volume: 22
  start-page: 72
  year: 2020
  ident: 789_CR53
  publication-title: Microbes Infect.
  doi: 10.1016/j.micinf.2020.02.006
– volume: 7
  start-page: e35421
  year: 2012
  ident: 789_CR55
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0035421
– ident: 789_CR96
  doi: 10.1172/JCI140200
– volume: 6
  start-page: 14
  year: 2020
  ident: 789_CR1
  publication-title: Cell Discov.
  doi: 10.1038/s41421-020-0153-3
– volume: 2
  start-page: 361
  year: 2016
  ident: 789_CR67
  publication-title: ACS Infect. Dis.
  doi: 10.1021/acsinfecdis.6b00006
– volume: 368
  start-page: 630
  year: 2020
  ident: 789_CR79
  publication-title: Science
  doi: 10.1126/science.abb7269
– volume: 9
  start-page: e01753-18
  year: 2018
  ident: 789_CR25
  publication-title: mBio
  doi: 10.1128/mBio.01753-18
– volume: 158
  start-page: e9
  year: 2020
  ident: 789_CR95
  publication-title: Chest
  doi: 10.1016/j.chest.2020.03.039
– ident: 789_CR27
– volume: 584
  start-page: 120
  year: 2020
  ident: 789_CR80
  publication-title: Nature
  doi: 10.1038/s41586-020-2381-y
– volume: 1
  start-page: 790
  year: 1988
  ident: 789_CR33
  publication-title: Lancet
  doi: 10.1016/S0140-6736(88)91657-1
– volume: 454–455
  start-page: 157
  year: 2014
  ident: 789_CR44
  publication-title: Virology
  doi: 10.1016/j.virol.2014.02.005
– volume: 25
  start-page: 729
  year: 2007
  ident: 789_CR70
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2006.08.011
– ident: 789_CR47
  doi: 10.1093/cid/ciaa344
– volume: 72
  start-page: 22
  year: 1968
  ident: 789_CR11
  publication-title: J. Pediatr.
  doi: 10.1016/S0022-3476(68)80396-8
– volume: 363
  start-page: 2122
  year: 2004
  ident: 789_CR72
  publication-title: Lancet
  doi: 10.1016/S0140-6736(04)16501-X
– ident: 789_CR51
  doi: 10.1016/j.cell.2020.08.017
– volume: 60
  start-page: 49
  year: 1998
  ident: 789_CR15
  publication-title: J. Vet. Med. Sci.
  doi: 10.1292/jvms.60.49
– volume: 583
  start-page: 282
  year: 2020
  ident: 789_CR3
  publication-title: Nature
  doi: 10.1038/s41586-020-2169-0
– ident: 789_CR7
  doi: 10.1101/2020.06.07.137802
– volume: 323
  start-page: 1582
  year: 2020
  ident: 789_CR92
  publication-title: JAMA
  doi: 10.1001/jama.2020.4783
– volume: 117
  start-page: 9490
  year: 2020
  ident: 789_CR93
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2004168117
– volume: 120
  start-page: 207
  year: 1991
  ident: 789_CR18
  publication-title: Arch. Virol.
  doi: 10.1007/BF01310476
– ident: 789_CR6
– volume: 89
  start-page: 422
  year: 1969
  ident: 789_CR9
  publication-title: Am. J. Epidemiol.
  doi: 10.1093/oxfordjournals.aje.a120955
– volume: 12
  start-page: 2351
  year: 2016
  ident: 789_CR59
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.1080/21645515.2016.1177688
– volume: 24
  start-page: 44
  year: 2005
  ident: 789_CR91
  publication-title: J. Clin. Microbiol. Infect. Dis.
  doi: 10.1007/s10096-004-1271-9
– volume: 428
  start-page: 561
  year: 2004
  ident: 789_CR71
  publication-title: Nature
  doi: 10.1038/nature02463
– volume: 108
  start-page: 20690
  year: 2011
  ident: 789_CR29
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1108360108
– volume: 23
  start-page: 2273
  year: 2005
  ident: 789_CR61
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2005.01.033
– volume: 86
  start-page: 4710
  year: 1989
  ident: 789_CR34
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.86.12.4710
– volume: 211
  start-page: 80
  year: 2015
  ident: 789_CR89
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiu396
– volume: 94
  start-page: e02015-19
  year: 2020
  ident: 789_CR39
  publication-title: J. Virol.
  doi: 10.1128/JVI.02015-19
– volume: 75
  start-page: 2324
  year: 2001
  ident: 789_CR35
  publication-title: J. Virol.
  doi: 10.1128/JVI.75.5.2324-2330.2001
– volume: 23
  start-page: 617
  year: 2018
  ident: 789_CR90
  publication-title: Antivir. Ther.
  doi: 10.3851/IMP3243
– volume: 111
  start-page: 5992
  year: 2014
  ident: 789_CR28
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1402458111
– volume: 3
  start-page: e525
  year: 2006
  ident: 789_CR56
  publication-title: PLoS Med.
  doi: 10.1371/journal.pmed.0030525
– volume: 20
  start-page: 656
  year: 2020
  ident: 789_CR48
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(20)30232-2
– volume: 35
  start-page: e149
  year: 2020
  ident: 789_CR94
  publication-title: J. Korean Med. Sci.
  doi: 10.3346/jkms.2020.35.e149
– volume: 62
  start-page: 111
  year: 2007
  ident: 789_CR12
  publication-title: Pediatr. Res.
  doi: 10.1203/PDR.0b013e3180686ce0
– volume: 9
  start-page: 1209
  year: 2003
  ident: 789_CR23
  publication-title: Nat. Med.
  doi: 10.1038/nm918
– volume: 8
  start-page: 317
  year: 2017
  ident: 789_CR20
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.00317
– volume: 116
  start-page: 15194
  year: 2019
  ident: 789_CR21
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1821317116
– volume: 355
  start-page: 395
  year: 2017
  ident: 789_CR30
  publication-title: Science
  doi: 10.1126/science.aai8128
– ident: 789_CR26
  doi: 10.1101/2020.05.18.099507
– volume: 8
  start-page: 687
  year: 2020
  ident: 789_CR31
  publication-title: Lancet Respir. Med.
  doi: 10.1016/S2213-2600(20)30193-4
– volume: 11
  start-page: 82
  year: 2014
  ident: 789_CR32
  publication-title: Virol. J.
  doi: 10.1186/1743-422X-11-82
– volume: 369
  start-page: 77
  year: 2020
  ident: 789_CR74
  publication-title: Science
  doi: 10.1126/science.abc1932
– volume: 181
  start-page: 6337
  year: 2008
  ident: 789_CR58
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.181.9.6337
– volume: 10
  start-page: 69
  year: 2019
  ident: 789_CR88
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.00697
– volume: 368
  start-page: 476
  year: 2020
  ident: 789_CR64
  publication-title: Science
  doi: 10.1126/science.abc1731
– ident: 789_CR52
  doi: 10.1126/science.abc8511
– volume: 367
  start-page: 1260
  year: 2020
  ident: 789_CR8
  publication-title: Science
  doi: 10.1126/science.abb2507
– volume: 4
  start-page: e123158
  year: 2019
  ident: 789_CR66
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.123158
– volume: 130
  start-page: 1545
  year: 2020
  ident: 789_CR99
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI138003
– volume: 33
  start-page: 201
  year: 2018
  ident: 789_CR68
  publication-title: Virol. Sin.
  doi: 10.1007/s12250-018-0009-2
– volume: 85
  start-page: 10582
  year: 2011
  ident: 789_CR40
  publication-title: J. Virol.
  doi: 10.1128/JVI.00671-11
– volume: 60
  start-page: 421
  year: 2003
  ident: 789_CR83
  publication-title: Adv. Virus. Res.
  doi: 10.1016/S0065-3527(03)60011-4
– ident: 789_CR54
  doi: 10.1101/2020.03.24.006544
– volume: 126
  start-page: 605
  year: 2016
  ident: 789_CR84
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI84428
– volume: 78
  start-page: 12672
  year: 2004
  ident: 789_CR60
  publication-title: J. Virol.
  doi: 10.1128/JVI.78.22.12672-12676.2004
– volume: 129
  start-page: 182
  year: 2019
  ident: 789_CR87
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI122466
– volume: 85
  start-page: 12201
  year: 2011
  ident: 789_CR57
  publication-title: J. Virol.
  doi: 10.1128/JVI.06048-11
– volume: 369
  start-page: m1443
  year: 2020
  ident: 789_CR49
  publication-title: BMJ
  doi: 10.1136/bmj.m1443
– volume: 89
  start-page: 2995
  year: 2015
  ident: 789_CR62
  publication-title: J. Virol.
  doi: 10.1128/JVI.02980-14
– volume: 64
  start-page: 1407
  year: 1990
  ident: 789_CR17
  publication-title: J. Virol.
  doi: 10.1128/jvi.64.3.1407-1409.1990
– volume: 11
  start-page: e0154461
  year: 2016
  ident: 789_CR43
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0154461
– volume: 101
  start-page: 6641
  year: 2004
  ident: 789_CR73
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0401939101
– volume: 79
  start-page: 7819
  year: 2005
  ident: 789_CR41
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.12.7819-7826.2005
– volume: 146
  start-page: 201
  year: 1977
  ident: 789_CR16
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.146.1.201
– volume: 11
  start-page: 1730
  year: 2005
  ident: 789_CR46
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid1111.040659
– volume: 367
  start-page: 1444
  year: 2020
  ident: 789_CR5
  publication-title: Science
  doi: 10.1126/science.abb2762
– volume: 26
  start-page: 1200
  year: 2020
  ident: 789_CR50
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0965-6
– volume: 10
  year: 2019
  ident: 789_CR85
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-08165-y
– volume: 209
  start-page: 1331
  year: 2014
  ident: 789_CR45
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jit504
– volume: 24
  start-page: 1028
  year: 2006
  ident: 789_CR69
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2005.06.038
– volume: 369
  start-page: 1010
  year: 2020
  ident: 789_CR78
  publication-title: Science
  doi: 10.1126/science.abd0827
– volume: 196
  start-page: 859
  year: 2002
  ident: 789_CR22
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20020781
– volume: 379
  start-page: 327
  year: 2018
  ident: 789_CR14
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1800820
– volume: 4
  start-page: 175
  year: 1981
  ident: 789_CR19
  publication-title: Comp. Immunol. Microbiol. Infect. Dis.
  doi: 10.1016/0147-9571(81)90003-5
– volume: 220
  start-page: 1558
  year: 2019
  ident: 789_CR63
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiz137
– volume: 181
  start-page: 271
  year: 2020
  ident: 789_CR4
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.052
– ident: 789_CR75
  doi: 10.1093/cid/ciaa325
– volume: 369
  start-page: 643
  year: 2020
  ident: 789_CR77
  publication-title: Science
  doi: 10.1126/science.abc5902
– ident: 789_CR98
– volume: 395
  start-page: 565
  year: 2020
  ident: 789_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30251-8
– volume: 328
  start-page: 745
  year: 2010
  ident: 789_CR13
  publication-title: Science
  doi: 10.1126/science.1185181
– volume: 52
  start-page: 65S
  issue: Suppl. 1
  year: 2012
  ident: 789_CR100
  publication-title: Transfusion
  doi: 10.1111/j.1537-2995.2012.03663.x
– volume: 26
  start-page: 186
  year: 2018
  ident: 789_CR38
  publication-title: Trends Microbiol.
  doi: 10.1016/j.tim.2017.10.004
– volume: 382
  start-page: 1969
  year: 2020
  ident: 789_CR65
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMp2005630
– volume: 34
  start-page: 3535
  year: 2016
  ident: 789_CR10
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2016.04.083
– volume: 449
  start-page: 101
  year: 2007
  ident: 789_CR86
  publication-title: Nature
  doi: 10.1038/nature06106
– volume: 77
  start-page: 7539
  year: 2003
  ident: 789_CR36
  publication-title: J. Virol.
  doi: 10.1128/JVI.77.13.7539-7544.2003
– volume: 36
  start-page: 217
  year: 1992
  ident: 789_CR37
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.1890360312
SSID ssj0001626686
Score 2.619581
SecondaryResourceType review_article
Snippet Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1185
SubjectTerms 13/1
631/250/255
631/61/24
Animals
Antibodies
Antibodies, Monoclonal - administration & dosage
Antibodies, Neutralizing - administration & dosage
Antibodies, Viral - administration & dosage
Antibodies, Viral - immunology
Antibody-Dependent Enhancement - immunology
Betacoronavirus - immunology
Biomedical and Life Sciences
Clinical trials
Coronavirus Infections - drug therapy
Coronavirus Infections - immunology
Coronavirus Infections - prevention & control
Coronavirus Infections - therapy
Coronaviruses
COVID-19
COVID-19 Drug Treatment
COVID-19 Serotherapy
COVID-19 Vaccines
Dengue fever
Humans
Immunization, Passive - adverse effects
In Vitro Techniques
Infectious Diseases
Life Sciences
Medical Microbiology
Microbiology
Models, Immunological
Pandemics - prevention & control
Parasitology
Perspective
Pneumonia, Viral - immunology
Pneumonia, Viral - prevention & control
Pneumonia, Viral - therapy
Respiratory syncytial virus
Respiratory Tract Diseases - etiology
Respiratory Tract Diseases - immunology
Risk Factors
Safety
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccines
Viral Vaccines - adverse effects
Viral Vaccines - immunology
Virology
Title Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
URI https://link.springer.com/article/10.1038/s41564-020-00789-5
https://www.ncbi.nlm.nih.gov/pubmed/32908214
https://www.proquest.com/docview/2474988359
https://www.proquest.com/docview/2441607890
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9swED62hMJexn61c9cVD_a2idiSbMtPI8kSwmBhJEvJm5ElmRaGnTXOIP_9dLacMMLyasu2uJPv7ruT7gP4mAQ0V0ZGRMaJBSgiDYkMuSJGpkWi44JHGoHi93k8W_Fv62jtEm5bt62ys4mNodaVwhz5gPKEp8LGC-mXzW-CrFFYXXUUGk-hb02wED3ojybzH4tjlsXG67GI3WmZgInBFhELJ4ia0D2mJPrXI52EmScl0sbzTF_Acxcy-sNWxy_hiSlfwUVLIrl_DV-HZf2QV3pPOkLb2jflPWoTM3--LLW_HC6WZFzdEer_kQpr6dvmenv6yoLlN7CaTn6OZ8RxIxDFw7QmzIJgY2gsA85yhqdNtbDOVstUqSihrJCxpnkkLcKwMZqWmhZSJbmkSWJoLkN2Cb2yKs1b8C3GMzoyiheGc2X9UyFyERQWmDBt8RT1IOzkkynXOBz5K35lTQGbiayVaWZlmjUyzSIPPh2e2bRtM86OvunEnrlfaJsdFe7Bh8Ntu_ixoiFLU-1wDMcGeSINPLhq1XX4HKPI5h5yDz53-ju-_P9zuT4_l3fwjOLaabbz3UCvftyZ9zYsqfNb6A-no9H81q3Bv_eK3lc
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrRC9IN4ECgQJTmA1sZ3EOSC09KEtbVeoD9Sb69iOioSSwqag_VP8Rmby2BWq6K3XxHGs8WfPfDMeD8CbLOKF9SZhJs2QoKg8ZiaWlnmTl5lLS5k4IooH03RyIj-fJqcr8GfIhaFjlcOe2G7UrrbkI9_gMpO5Qnsh_3jxg1HVKIquDiU0Oljs-flvpGyzD7tbOL9vOd_ZPt6csL6qALMyzhsmkD56z1MTSVEIytN0CtWUM7m1ScZFaVLHi8SgbY7WjTOOl8ZmheFZ5nlhYoH93oJVKdKIj2D10_b0y-HSq4P8IFVpn50TCbUxI4YkGbE0Usc5S_7VgFfM2ish2VbT7dyDu72JGo47TN2HFV89gNtd0cr5Q9gaV823onZzNhTQbUJfnRN6yNMYmsqFR-PDI7ZZf2U8_GUsxe5n7fMu2wvJ-SM4uRGpPYZRVVf-KYTIKb1LvJWll9KiPixVoaISiZBwyN94APEgH237i8qpXsZ33QbMhdKdTDXKVLcy1UkA7xbfXHTXdFzben0Qu-6X7EwvARbA68VrXGwUQTGVry-pjaQL-VQeBfCkm67F7wSn6vGxDOD9MH_Lzv8_lmfXj-UV3JkcH-zr_d3p3nNY44Sj9ijhOoyan5f-BZpETfGyx2EIZzcN_b-dpBp9
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibody-dependent+enhancement+and+SARS-CoV-2+vaccines+and+therapies&rft.jtitle=Nature+microbiology&rft.au=Lee%2C+Wen+Shi&rft.au=Wheatley%2C+Adam+K.&rft.au=Kent%2C+Stephen+J.&rft.au=DeKosky%2C+Brandon+J.&rft.date=2020-10-01&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2058-5276&rft.volume=5&rft.issue=10&rft.spage=1185&rft.epage=1191&rft_id=info:doi/10.1038%2Fs41564-020-00789-5&rft.externalDocID=10_1038_s41564_020_00789_5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2058-5276&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2058-5276&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2058-5276&client=summon